Blockbuster obesity drugs currently on the market from Novo Nordisk and Eli Lilly both work by targeting GPCRs. In Novo Nordisk’s case, its Wegovy treatment targets a GPCR known as GLP-1, ...

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

Novo Nordisk on Wednesday said it will collaborate ... The companies will use Septerna’s technology for crafting drugs that can work on so-called G protein-coupled receptors, or GPCRs.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...

According to the heat map I created, which distributes the winner by each parameter, Eli Lilly scored 7 points, while Novo Nordisk only 2. As a result, Eli Lilly is the winner in this category by ...

Novo Nordisk is doubling down on its collaboration ... gave Novo three cardiovascular assets and set the stage for work on up to 11 programs overall. Novo was primarily focused on cardiovascular ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...